Relationships of blood proinflammatory markers with psychological resilience and quality of life in civilian women with posttraumatic stress disorder.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 11 2019
29 11 2019
Historique:
received:
31
07
2019
accepted:
15
11
2019
entrez:
1
12
2019
pubmed:
1
12
2019
medline:
3
11
2020
Statut:
epublish
Résumé
Individuals with posttraumatic stress disorder (PTSD) show low resilience and impaired quality of life (QOL). Accumulating evidence shows that PTSD is associated with increased inflammation. Studies suggest that inflammation can be a key mechanism underlying low resilience/QOL, but this relationship has been understudied in individuals with PTSD. Here, we investigated the association of blood proinflammatory markers with self-reported resilience and QOL in civilian women with PTSD. Fifty-six women with PTSD and 73 healthy control women participated in this study. Resilience was assessed using the Connor-Davidson Resilience Scale. QOL was assessed using the World Health Organization Quality of Life-BREF. Blood samples were collected for the measurement of three proinflammatory markers including interleukin-6 (IL-6), high-sensitivity tumor necrosis factor-α, and high-sensitivity C-reactive protein (hsCRP). Compared to controls, patients showed significantly higher IL-6 levels and lower resilience and QOL. In patients, IL-6 levels were significantly negatively correlated with resilience, and hsCRP levels were significantly negatively correlated with psychological QOL. These results show that increased levels of proinflammatory markers including IL-6 and hsCRP are associated with lower psychological resilience and QOL in PTSD patients. Our findings suggest that interventions and treatments targeting inflammation may aid in the recovery from PTSD and lead to better prognosis.
Identifiants
pubmed: 31784695
doi: 10.1038/s41598-019-54508-0
pii: 10.1038/s41598-019-54508-0
pmc: PMC6884570
doi:
Substances chimiques
Biomarkers
0
Interleukin-6
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17905Références
Am Heart J. 2013 Nov;166(5):806-14
pubmed: 24176435
Lancet Psychiatry. 2015 Nov;2(11):1002-12
pubmed: 26544749
Exp Neurol. 2016 Oct;284(Pt B):220-229
pubmed: 27246996
JAMA Psychiatry. 2014 Apr;71(4):423-31
pubmed: 24576974
Brain Behav Immun. 2018 Nov;74:28-42
pubmed: 30102966
Psychiatry Clin Neurosci. 2019 Apr;73(4):143-153
pubmed: 30653780
Brain Behav Immun. 2018 Jan;67:194-202
pubmed: 28867284
Biol Psychiatry. 2018 May 15;83(10):866-875
pubmed: 29628193
J Psychosom Res. 2013 Apr;74(4):301-6
pubmed: 23497831
Braz J Psychiatry. 2017 Apr-Jun;39(2):172-179
pubmed: 27901215
Neurosci Biobehav Rev. 2018 Nov;94:76-92
pubmed: 30067939
Sci Rep. 2015 Jun 04;5:10793
pubmed: 26041435
J Trauma. 2002 Nov;53(5):882-8
pubmed: 12435938
Brain Behav Immun. 2017 Feb;60:198-205
pubmed: 27765647
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Asian J Psychiatr. 2017 Feb;25:1-5
pubmed: 28262126
Health Psychol. 2017 Nov;36(11):1047-1058
pubmed: 28825494
J Affect Disord. 2018 Oct 1;238:399-404
pubmed: 29909303
J Nerv Ment Dis. 2002 Mar;190(3):175-82
pubmed: 11923652
JAMA Psychiatry. 2016 Jul 1;73(7):695-704
pubmed: 27167565
Aliment Pharmacol Ther. 2015 Mar;41(6):497-520
pubmed: 25616122
Psychiatry Clin Neurosci. 2013 Sep;67(6):420-5
pubmed: 23910517
Psychol Med. 2017 Oct;47(13):2260-2274
pubmed: 28385165
Health Qual Life Outcomes. 2014 Sep 28;12:141
pubmed: 25260501
Am J Psychiatry. 2015 Apr;172(4):353-62
pubmed: 25827033
Psychiatry Res. 2014 Apr 30;216(1):116-22
pubmed: 24559851
J Affect Disord. 2018 Feb;227:494-497
pubmed: 29156363
Proc Natl Acad Sci U S A. 2010 May 18;107(20):9470-5
pubmed: 20439746
Front Psychiatry. 2014 Apr 09;5:34
pubmed: 24782789
Transl Psychiatry. 2014 Jul 22;4:e413
pubmed: 25050993
Dev Psychopathol. 2011 Nov;23(4):1139-47
pubmed: 22018086
Biol Psychiatry. 2015 Feb 15;77(4):365-74
pubmed: 25104173
J Psychosom Res. 2000 Jun;48(6):555-60
pubmed: 11033374
Neuropsychopharmacology. 2015 Jun;40(7):1709-16
pubmed: 25598426
Psychiatry Clin Neurosci. 2005 Oct;59(5):517-26
pubmed: 16194252
Dev Psychopathol. 2007 Summer;19(3):889-920
pubmed: 17705907
Health Qual Life Outcomes. 2019 Feb 6;17(1):26
pubmed: 30728031
Ann Behav Med. 2017 Oct;51(5):782-786
pubmed: 28281135
Int Psychogeriatr. 2019 Feb;31(2):193-202
pubmed: 29335041
Neurosci Biobehav Rev. 2010 Sep;35(1):33-8
pubmed: 19751761
J Affect Disord. 2013 Dec;151(3):973-9
pubmed: 24103854
Psychiatry Res. 2018 Feb;260:193-198
pubmed: 29202383
Brain Behav Immun. 2011 Mar;25(3):524-31
pubmed: 21145962
Neuropsychopharmacology. 2018 Feb;43(3):469-481
pubmed: 28925389
Brain Behav Immun. 2009 Jul;23(5):643-8
pubmed: 19133324
Mol Psychiatry. 2015 Dec;20(12):1538-45
pubmed: 25754082
Aust N Z J Psychiatry. 2006 Apr;40(4):355-61
pubmed: 16620318
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Soc Cogn Affect Neurosci. 2018 Sep 5;13(8):851-862
pubmed: 30016499
J Psychiatr Res. 2018 Jul;102:192-200
pubmed: 29684628
Nat Rev Neurosci. 2008 Jan;9(1):46-56
pubmed: 18073775
Brain Behav Immun. 2017 Jan;59:260-264
pubmed: 27638184
Compr Psychiatry. 2017 Apr;74:125-133
pubmed: 28160694
Lancet Psychiatry. 2019 Mar;6(3):247-256
pubmed: 30798897
Am J Geriatr Psychiatry. 2015 Jul;23(7):709-25
pubmed: 25959921
Depress Anxiety. 2003;18(2):76-82
pubmed: 12964174
Psychosom Med. 2008 Jul;70(6):668-76
pubmed: 18596248
J Neurosci Res. 2017 Sep;95(9):1760-1775
pubmed: 28029706
Qual Life Res. 2006 Feb;15(1):15-24
pubmed: 16411027
Acta Psychiatr Scand. 2016 Oct;134(4):360-7
pubmed: 27497263